OBJECTIVE: The objective of the study was to examine outcomes in stage IB2 cervical cancer patients undergoing primary surgery versus radiation. METHODS: Stage IB2 cervical cancer patients were identified from the Surveillance, Epidemiology and End Results Public-Use Database from 2000 to 2006. Patients were divided into those receiving radiation (radiation first) or surgery (surgery first) as initial treatment. Overall survival was calculated by Kaplan-Meier method and compared using log-rank test. RESULTS: In total, 770 patients were identified with stage IB2 cervical cancer; 369 received radiation, and 401 received surgery initially. The radiation-first group had larger mean tumor size than the surgery-first group (6.0 vs 5.5 cm, respectively; P < 0.0001). The overall survival was longer in the surgery-first group compared with the radiation-first group (72.0 vs 61.4 months, respectively; P < 0.0001). CONCLUSIONS: Patients undergoing surgery as initial treatment for stage IB2 cervical cancer appear to have improved outcomes in the current era of chemoradiation; however, given the lack of chemotherapy information, a randomized trial will be necessary to see if these results remain valid.
OBJECTIVE: The objective of the study was to examine outcomes in stage IB2 cervical cancerpatients undergoing primary surgery versus radiation. METHODS: Stage IB2 cervical cancerpatients were identified from the Surveillance, Epidemiology and End Results Public-Use Database from 2000 to 2006. Patients were divided into those receiving radiation (radiation first) or surgery (surgery first) as initial treatment. Overall survival was calculated by Kaplan-Meier method and compared using log-rank test. RESULTS: In total, 770 patients were identified with stage IB2 cervical cancer; 369 received radiation, and 401 received surgery initially. The radiation-first group had larger mean tumor size than the surgery-first group (6.0 vs 5.5 cm, respectively; P < 0.0001). The overall survival was longer in the surgery-first group compared with the radiation-first group (72.0 vs 61.4 months, respectively; P < 0.0001). CONCLUSIONS:Patients undergoing surgery as initial treatment for stage IB2 cervical cancer appear to have improved outcomes in the current era of chemoradiation; however, given the lack of chemotherapy information, a randomized trial will be necessary to see if these results remain valid.
Authors: Leslie H Clark; Emma L Barber; Paola A Gehrig; John T Soper; John F Boggess; Kenneth H Kim Journal: Int J Gynecol Cancer Date: 2016-10 Impact factor: 3.437
Authors: Vivek Nama; Georgios Angelopoulos; Jeremy Twigg; John B Murdoch; Jo Bailey; Theresa A Lawrie Journal: Cochrane Database Syst Rev Date: 2018-10-12
Authors: Jung-Yun Lee; Jina Youm; Jae Weon Kim; Kidong Kim; Hak Jae Kim; Jeong Yeon Cho; Min A Kim; Noh Hyun Park; Yong-Sang Song Journal: Cancer Res Treat Date: 2015-03-20 Impact factor: 4.679